Press coverage about StemlineTherapeutics (NASDAQ:STML) has been trending somewhat positive this week, Accern Sentiment reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. StemlineTherapeutics earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.2993376963629 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual … (globenewswire.com)
- Stemline Therapeutics Announces Presentation of SL-801 and SL-701 Clinical Data at the Upcoming ASCO Annual Meeting (finance.yahoo.com)
- Is Earnings Growth Happening For Stemline Therapeutics, Inc. (NasdaqCM:STML)? (derbynewsjournal.com)
- ValuEngine Lowers StemlineTherapeutics (STML) to Hold (americanbankingnews.com)
- Zacks: Analysts Anticipate StemlineTherapeutics Inc. (STML) to Announce -$0.63 EPS (americanbankingnews.com)
StemlineTherapeutics opened at $19.50 on Friday, according to MarketBeat Ratings. The stock has a market capitalization of $581.26 million, a PE ratio of -6.63 and a beta of 0.01. StemlineTherapeutics has a twelve month low of $19.10 and a twelve month high of $19.30.
STML has been the subject of a number of research analyst reports. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of StemlineTherapeutics in a report on Friday, February 2nd. ValuEngine upgraded shares of StemlineTherapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub upgraded shares of StemlineTherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 27th. Finally, Zacks Investment Research downgraded shares of StemlineTherapeutics from a “hold” rating to a “sell” rating in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $27.00.
In other news, insider David Gionco sold 8,984 shares of StemlineTherapeutics stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $17.43, for a total value of $156,591.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Kenneth Hoberman sold 3,027 shares of StemlineTherapeutics stock in a transaction dated Wednesday, March 7th. The stock was sold at an average price of $16.55, for a total transaction of $50,096.85. The disclosure for this sale can be found here. Insiders sold 132,457 shares of company stock valued at $2,286,115 in the last quarter. Corporate insiders own 16.70% of the company’s stock.
Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.
Receive News & Ratings for StemlineTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemlineTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.